Catalyst Brief

← Calendar

Readoutin 14d

Chia Tai Tianqing Pharmaceutical Group Co., Ltd. — AK105 Injection

Phase 3 primary completion: A Phase III Clinical Trial of AK105 Injection Combined With Anlotinib Hydrochloride Capsules Versus Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (HCC).

Date
Dec 2026
Type
Readout
Indication
Advanced Hepatocellular Carcinoma (HCC)

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

  1. Jan2027
  2. Dec2026